Get the Stockscreener App
1.01
0.98%
-0.01
After Hours:
1.03
0.02
+1.98%
Phio Pharmaceuticals Corp stock is traded at $1.01, with a volume of 238.49K.
It is down -0.98% in the last 24 hours and down -15.13% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.
See More
Previous Close:
$1.02
Open:
$1.0299
24h Volume:
238.49K
Relative Volume:
0.41
Market Cap:
$11.73M
Revenue:
-
Net Income/Loss:
$-10.93M
P/E Ratio:
-0.7025
EPS:
-1.4378
Net Cash Flow:
$-10.72M
1W Performance:
-1.94%
1M Performance:
-15.13%
6M Performance:
-19.84%
1Y Performance:
-54.09%
1-Day Range:
$0.9872
$1.05
1-Week Range:
$0.9872
$1.05
52-Week Range:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.01 | 11.73M | 0 | -10.93M | -10.72M | -1.4378 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-25 | Resumed | H.C. Wainwright | Buy |
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
Director Patricia Bradford Buys 6,500 Shares of Phio Pharmaceuti - GuruFocus
At $1.0127 a share, a Phio Pharmaceuticals (PHIO) director bought 6,500 shares. - Stock Titan
Phio Pharmaceuticals to Present Clinical Development Update - openPR.com
Phio Pharmaceuticals to Present Clinical Development Update & Upc - natlawreview.com
A CEO buys Phio Pharmaceuticals (PHIO) shares at $1.0289 each; reported direct holdings total 364,871 shares. - Stock Titan
Phio Pharmaceuticals Corp. (PHIO) Stock Price, News, Quote & History - Yahoo! Finance Canada
A potential skin cancer treatment completed a clinical study. Phio will discuss next steps Sept. 30. - Stock Titan
Live Phio Pharmaceuticals Corp. (PHIO) Technical Analysis - Traders Union
Phio Pharmaceuticals Corp. Stock Price Prediction: Today, Tomorrow, Next Week (PHIO) - Traders Union
Phio Pharmaceuticals Corp. (PHIO) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Phio Pharmaceuticals Corp (NASDAQ: PHIO) Share Price, PHIO Stock News, PHIO Share Price & Updates - kalkine.com.au
Phio Pharmaceuticals (NASDAQ: PHIO) Director Patricia A. Bradford Acquires 12,000 Shares at $1.03 Each - Kalkine Media
Phio Pharmaceuticals (PHIO) director buys shares with no 10b5-1 plan reported - Stock Titan
Phio Pharmaceuticals (PHIO) CEO has 68,550 shares withheld for taxes - Stock Titan
Phio Announces Key Development Milestone for PH-762 with FDA - openPR.com
Phio Pharmaceuticals (PHIO) CFO’s 12,888-share tax move involves no market sale - Stock Titan
Phio Announces PH-762 Milestone with FDA Submission Supporting Clinical Development in Cutaneous Squamous Cell Carcinoma - EIN News
Form 8K Phio Pharmaceuticals Corp For: 14 September By Investing.com - Investing.com Nigeria
King of Prussia's Phio Pharmaceuticals Submits FDA Briefing Package to Advance Its Skin Cancer Gene-Silencing Therapy - BioBuzz
Phio Advances PH-762 Toward Phase 2b Skin Cancer Trial - TipRanks
Phio Pharmaceuticals submits FDA briefing for PH-762 study By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals submits FDA briefing for PH-762 study - Investing.com
Plans for a skin-cancer study reach the FDA after Phio completes an early trial - Stock Titan
Phio Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference - openPR.com
Phio Pharmaceuticals to present clinical updates on cancer treatment PH-762 at H.C. Wainwright conference - Pluang
A potential nonsurgical treatment for skin cancers will be discussed at an investor conference - Stock Titan
PHIO Q2 2026 Earnings: EPS of -$0.36 Slightly Beats Consensus as Company Remains Pre-RevenueCEO Earnings Statement - dars.gov.et
Phio Pharmaceuticals Corp (PHIOW) Key Financial Ratios – Valuation, Profitability & More - Value Research
PHIO Should I Buy - Intellectia AI
Phio Pharmaceuticals director Plott buys $17,100 in shares - Investing.com
Phio Pharmaceuticals director Plott buys $17,100 in shares By Investing.com - Investing.com Canada
Phio Pharmaceuticals (PHIO) director snaps up 15,000 shares - stocktitan.net
Price to sales forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals (PHIO) Chairman Robert Bitterman Buys 10,00 - GuruFocus
Phio Pharmaceuticals (PHIO) CEO boosts holdings to 431,421 shares - Stock Titan
Price to earnings forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Price to earnings forward of Phio Pharmaceuticals Corp. – BOATS:PHIO - TradingView
Phio Pharmaceuticals Corp. SEC Filing (Aug 14, 2026) - Stock Titan
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Compound PH-894 Targeting BRD4 Protein - The National Law Review
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 By Investing.com - Investing.com Nigeria
Phio Pharmaceuticals receives U.S. patent allowance for PH-894 - Investing.com
Phio Pharma wins U.S. patent allowance for BRD4-targeting INTASYL compound PH-894 - Bitget
Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894 - TMX Newsfile
Phio Pharmaceuticals Receives U.S. Notice of Allowance for PH-894 Patent Targeting BRD4 Protein via INTASYL® Platform - kalkine.ca
Enterprise value to revenue forward of Phio Pharmaceuticals Corp. – NASDAQ:PHIO - TradingView
Phio Pharmaceuticals Corp (PHIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Phio Pharmaceuticals Corp. Q2 2026: Net income $(4.14)M, EPS $(0.36) — 10-Q Summary - TradingView
Phio Pharmaceuticals posts $4.1M Q2 net loss, cash $13.0M; advances PH-762 program - TradingView
PHIO: PH-762 clinical progress accelerates as cash runway extends into 2027 amid rising R&D costs - TradingView
PHIO: Q2 2026 net loss widened to $4.1M as PH-762 advanced, with $13M in cash and ongoing funding needs - TradingView
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update - TMX Newsfile
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):